Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 29, 2023 -- ProMIS Neurosciences Inc. , a biotechnology company focused on the generation and development of antibody therapeutics... | March 29, 2023